Company Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors.
It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Lawrence Blatt |
Contact Details
Address: One Corporate Drive, 2nd Floor South San Francisco, California 94080 United States | |
| Phone | 800 466 6059 |
| Website | aligos.com |
Stock Details
| Ticker Symbol | ALGS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001799448 |
| CUSIP Number | 01626L105 |
| ISIN Number | US01626L1052 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence M. Blatt MBA, Ph.D. | Chief Executive Officer, President and Chairman of the Board |
| Dr. Julian A. Symons DPHIL | Executive Vice President and Chief Scientific Officer |
| Lesley Ann Calhoun CPA | Executive Vice President and Chief Financial Officer |
| Kristina Engeseth | Vice President and Head of People and Culture |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President and Chief Development Officer |
| Dr. David B. Smith Ph.D. | Executive Vice President and Head of Chemical Operations |
| Dr. Tse-I Lin Ph.D. | Vice President of Early Compound Development and Belgian Site Head |
| Dr. Hardean E. Achneck M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | EFFECT | Notice of Effectiveness |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 6, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 6, 2024 | 10-Q | Quarterly Report |